Fosfomycin – Investigation of a possible new route of administration of an old drug A case study by Cree, Michele et al.
Journal of Cystic Fibrosis 6 (2007) 244–246
www.elsevier.com/locate/jcfCase studies
Fosfomycin – Investigation of a possible new route
of administration of an old drug
A case study
Michele Cree a,⁎, Sonya Stacey a, Nicolette Graham a, Claire Wainwright b
a Pharmacy Department, Royal Children's Hospital, Brisbane, Australia
b Department of Respiratory Medicine, Royal Children's Hospital, Brisbane, Australia
Received 11 January 2006; received in revised form 3 May 2006; accepted 27 August 2006
Available online 18 October 2006Abstract
Patients with cystic fibrosis can develop multi-resistant organisms and may have poor intravenous access making antibiotic treatment
difficult. This case discusses the successful use of fosfomycin via the subcutaneous route in a paediatric patient with cystic fibrosis.
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The antibacterial effects of fosfomycin are related to the
inhibition of bacterial cell wall synthesis. Fosfomycin inac-
tivates the enzyme pyruvyl transferase which is required for
the synthesis of the cell wall peptidoglycan by bacteria [1–4].
It has activity against a range of Gram-positive and Gram-
negative bacteria including some strains of Pseudomonas
aeruginosa [1,2]. It has synergistic antimicrobial effects with
aminoglycosides and beta-lactams [1]. Fosfomycin has been
used successfully to treat adult patients with cystic fibrosis [3].
It is approved by the Food and Drug Administration (FDA) of
the United States of America for the treatment of urinary tract
infections. It is not approved in Australia, but is available via
the Special Access Scheme fromSanofi-Synthelabo. Themain
side effects reported have been gastrointestinal (nausea, vomit-
ing and diarrhoea), and transient increases in serum transam-
inase levels thought to be more common in oral than in i.v.
route [3]. Localised reactions (irritation and pain) at the site of
administration have been reported with i.v. therapy [3]. The
recommended i.v. dose for adults is 4 g three times a day,⁎ Corresponding author.
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intravenously over 4 h [4].
2. Case report
Our patient was a 14-year-old girl (36 kg) with cystic
fibrosis diagnosed through neonatal screening (ΔF508
homozygous). She had significant progressive suppurative
lung disease, and moderate bronchiectasis with the best
respiratory function tests in the last 12 months of FEV1 70%
and FVC 72% predicted. The patient had experienced
frequent hospital admissions for respiratory exacerbations,
with sputum cultures positive for mucoid and non-mucoid
multi-resistant P. aeruginosa (only sensitive to colistin), and
Staphylococcus aureus. Sensitivity testing for fosfomycin
was unavailable. The patient had a history of multiple drug
allergies to ceftazidime, Timentin®, imipenem, meropenem,
aztreonam and flucloxacillin. Intravenous access was limited.
Recurrent infections and thrombosis had resulted in the
failure of eight central venous devices and SVC obstruction.
No further central venous access devices were thought to be
possible after discussion with vascular surgeons. Peripheral
venous access was difficult, lasting only 12 to 24 h and
further complicated by needle phobia. Other novel regimens
such as AV fistula and continuous subcutaneous ceftazidimeB.V. on behalf of European Cystic Fibrosis Society.All rights reserved.
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Alternate modes of drug administration were investigated to
treat multi-resistant P. aeruginosa.
Fosfomycin was proposed to be administered subcutane-
ously as it is effective against multi-resistant P. aeruginosa
[1–3] and although traditionally given intravenously, intra-
muscular administration of fosfomycin has been reported
[7,8]. Direct tissue damage did not appear to be a concern,
however multiple intramuscular injections were not appro-
priate in this child due to low muscle bulk, patient discomfort
and tolerability. Fosfomycin was reported to have bacterial
cell killing characteristics appropriate for continuous infusion
[8] and a continuous subcutaneous infusion was planned. The
concentration for infusion was cause for concern as the drug
itself is extremely alkaline. The diluent provided by the
manufacturer contains succinic acid to reduce the pH, and it is
recommended to dilute the infusion further before adminis-
tration [4]. Nebulised fosfomycin was not considered as it
was likely to be an irritant and the patient did not usually
tolerate nebulised medications. A dose of 7200 mg/day was
proposed (200 mg/kg/day) as a continuous infusion at
concentration 300 mg/mL (1 mL/h).
The patient received several treatment courses of
fosfomycin. In the first treatment course the patient tolerated
the first day of treatment at the proposed dose and
concentration, then complained of swelling at the injection
site. The infusion volume was decreased (by increasing the
concentration to 280 mg/h (0.7 mL/h)) to minimise erythema
and pain. The infusion was restarted after resiting the in-
dwelling subcutaneous catheter. The patient received a total
of 5 days of therapy, before ceasing therapy due to erythema
and pain at the injection site. FEV1 improved from 70% to
77%. The patient's usual medications were continued, with
the addition of nebulised colistin during this admission.
In the second treatment, fosfomycin was recommenced
several months later (at patient's request) at 7200 mg over
24 h, with oral ciprofloxacin. The patient complained of
tenderness and hardness at the injection site, therefore the
dose and concentration were modified over several days to
increase the concentration and decrease the volume. Final
dose tolerated was 5760 mg over 24 h at 0.6 mL/h (400 mg/
mL). The insuflon® was resited every 48 h and therapy
continued for 14 days. The patient's respiratory function tests
improved significantly on this occasion with FEV1 from 44%
to 68% predicted, the best result in the past 12 months.
With the third treatment the patient was commenced on
continuous subcutaneous fosfomycin at the same dose as the
previous admission (5760 mg over 24 h at 0.6 mL/h (400 mg/
mL)), with oral ciprofloxacin. This admission was complicated
by severe haemoptysis. The patient received 5 days of treatment
of fosfomycin, with intermediate doses of i.v. tobramycin when
i.v. access was available and improved marginally from 46% to
51% predicted. Treatment was again complicated by localised
reactions (hardness, swelling and tenderness) which settled
following cessation of therapy although the induration took
several weeks to resolve.3. Discussion
Patients with cystic fibrosis who are chronically infected
with P. aeruginosa generally require multiple courses of anti-
pseudomonal antibiotics for respiratory exacerbations. The
repeated use of a limited selection of antibiotics encourages
the development of resistance, and multi-resistant P.
aeruginosa strains [3] may emerge. Fosfomycin given
intravenously in combination with other antibiotics for
respiratory exacerbations in cystic fibrosis patients colonised
with multi-resistant P. aeruginosa resulted in clinical
improvement (including improvement in FEV1) with a low
adverse effect profile [3]. Fosfomycin characteristics allow it
to be given effectively as a continuous infusion remaining
above the mean inhibitory concentration (MIC). TheMIC for
P. aeruginosa has been reported to be from 0.25 to 128 μg/mL
[3,4]. Unfortunately assays were not available to measure
fosfomycin levels in this patient.
This case illustrates the potential for administration of
subcutaneous fosfomycin in an adolescent with cystic
fibrosis. Under fosfomycin therapy the respiratory function
of our patient improved in one of the treatment courses
where sufficient days of therapy were tolerated.
When intravenous access is difficult or unavailable, alter-
native modes of administration are required. Factors such as
dose, concentration, pH, rate of infusion, choice of device,
stability, andmanagement of adverse effectswere all important
considerations in the management of this patient. No serious
adverse effects were noted during the treatment courses, al-
though the localised reactions at the infusion site limited
patient tolerability.
4. Conclusion
Only one complete course of continuous subcutaneous
fosfomycin was tolerated and found to be successful for
this patient although shorter courses were also useful in
treating respiratory exacerbations, shown by improved res-
piratory function tests. No serious adverse effects were
noted during the treatment courses although the localised
reactions at the infusion site limited patient tolerability. The
pharmacokinetics and role of subcutaneous administration
of antibiotics require further evaluation and investigation
for future use.
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